DeutschNewstral
Article
The Times of India on 2021-11-25 00:21
Covid-19: Why 50% Covaxin efficacy may not be as bad as it seems
Related news
Updated data from Covaxin phase 3 trial shows 78% efficacyThe Hindu- Covaxin safe, shows 77.8% efficacy against symptomatic COVID-19: Lancet studyThe Hindu
- Bharat Biotech releases Covaxin Phase-3 trial data, claims 77.8% efficacyThe Hindu
- Bharat Biotech says COVID-19 vaccine Covaxin shows 81% interim efficacyThe Hindu
- Covaxin phase 3 data shows 77.8% efficacy: LancetThe Times of India
- Hospital apologises as ‘Covaxin for kids’ poster goes viralThe Times of India
- 50 mn doses of Covaxin set to expire early 2023 due to poor off takeThe Hindu
- Man given first dose of Covaxin as phase-1 human clinical trial begins at AIIMSThe Hindu
Israeli study on 4th shots for COVID is bad news — but not as bad as it seemstimesofisrael.com- Australia recognises CovaxinThe Times of India
- 'Covishield, Covaxin can protect against Omicron'The Times of India
- ‘Vaccine with even 50% efficacy may be cleared’The Times of India
- Covaxin gave lower protection during second wave: Real-world studyThe Times of India
Friday Squid Blogging: On the Efficacy of Squid as Baitschneier.com- India-made Covaxin gets WHO approval, can be used globallyThe Times of India
- Month after month, Covaxin missing production targetThe Times of India
- Covaxin effective against Delta Plus variant: ICMRThe Times of India
- Covid-19: Switzerland accepts Covaxin, UK could do so shortlyThe Times of India
- Coronavirus | Covaxin phase-1 trial results show promising resultsThe Hindu
- CNot quite as bad as it seemscitizen.on.ca